Recently we analyzed, for the therapeutic PSMA ligand [177Lu]Lu-PSMA I&T, the time- and absorbed dose-dependent induction and repair of DSBs with a DNA damage focus assay that utilizes immunofluorescent staining with antibodies for γ-H2AX and 53BP1 DNA DSB damage markers [4,5,6] and the analysis of co-localized γ-H2AX+53BP1 foci in the cell nuclei of peripheral blood leukocytes of prostate cancer patients to assess DSB damage [7]. This evidence concerns the gene TP53BP1 and prostate carcinoma.